Venture Visionary Partners LLC Buys 472 Shares of Thermo Fisher Scientific Inc. $TMO

Venture Visionary Partners LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.6% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 3,707 shares of the medical research company’s stock after purchasing an additional 472 shares during the period. Venture Visionary Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,503,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Mondrian Investment Partners LTD boosted its holdings in shares of Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock valued at $106,738,000 after buying an additional 127,357 shares during the last quarter. Foresight Group Ltd Liability Partnership boosted its position in Thermo Fisher Scientific by 3,242.7% during the first quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company’s stock worth $29,113,000 after purchasing an additional 56,747 shares during the period. Advisors Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 6.7% in the first quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company’s stock valued at $63,201,000 after purchasing an additional 7,967 shares during the last quarter. New England Research & Management Inc. raised its holdings in Thermo Fisher Scientific by 28.6% in the 2nd quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company’s stock valued at $1,033,000 after acquiring an additional 567 shares during the period. Finally, IMS Capital Management acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $343,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 4.9%

Shares of TMO stock opened at $484.70 on Wednesday. The firm has a market cap of $183.03 billion, a P/E ratio of 28.03, a price-to-earnings-growth ratio of 2.51 and a beta of 0.75. The business has a 50-day moving average price of $478.98 and a two-hundred day moving average price of $446.98. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $620.00. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business’s revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This represents a 0.35% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on TMO shares. Raymond James Financial restated an “outperform” rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. William Blair assumed coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating on the stock. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a research report on Thursday, July 24th. Finally, Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday, September 7th. Fifteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $583.53.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.